Balaxi Pharma (BALAXI)
Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹24 |
| Market Cap | ₹132.5 Cr |
| P/E Ratio | 92.31 |
| ROCE | 12.95% |
| ROE | 0.59% |
| Dividend Yield | 0% |
| Profit Growth | -92.9% |
| Debt/Equity | 0.23 |
| Sales Growth | -7.3% |
| Promoter Holding | 65.99% |
| 52-Week Range | ₹15.2 — ₹43.85 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹45.12 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At first glance, Balaxi Pharma looks like a typical Graham cigar butt. The market cap is just ₹109 crore, while the book value per share is ₹45.56. Buying at ₹27.50 means you are paying only 60 paise for each rupee of equity. The balance sheet supports this view—debt-to-equity is a modest 0.24, and return on capital employed is 12.95%. But a value investor must separate a bargain from a value trap. The profit picture is alarming: profit growth has crashed by 94.22%, and the latest quarter shows sales of ₹73 crore but net profit of zero. A business that cannot convert revenue into earnings is not a compounding machine. The Piotroski F-score of 3/9 confirms deteriorating fundamentals—this is not a high-quality business.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer